The global Primary Immunodeficiency Therapeutic Market growth is projected to reach US$ 521 million in 2025 to US$ 732 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.

Global Primary Immunodeficiency Therapeutic Market Growth And Outlook 2025-31

The global Primary Immunodeficiency Therapeutic market size is predicted to grow from US$ 521 million in 2025 to US$ 732 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031. Primary immunodeficiencies are a group of different disorders in which part of the bodys immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the ?Primary Immunodeficiency Therapeutic Industry Forecast? looks at past sales and reviews total world Primary Immunodeficiency Therapeutic sales in 2024, providing a comprehensive analysis by region and market sector of projected Primary Immunodeficiency Therapeutic sales for 2025 through 2031. With Primary Immunodeficiency Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Immunodeficiency Therapeutic industry. This Insight Report provides a comprehensive analysis of the global Primary Immunodeficiency Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Primary Immunodeficiency Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Primary Immunodeficiency Therapeutic market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Immunodeficiency Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Immunodeficiency Therapeutic. This report presents a comprehensive overview, market shares, and growth opportunities of Primary Immunodeficiency Therapeutic market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Immunoglobulin Replacement Therapy &nbsp;&nbsp;&nbsp; Stem Cell or Bone Marrow Transplantation &nbsp;&nbsp;&nbsp; Antibiotic Therapy &nbsp;&nbsp;&nbsp; Gene Therapy &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Antibody Deficiency &nbsp;&nbsp;&nbsp; Cellular Immunodeficiency &nbsp;&nbsp;&nbsp; Innate Immune Disorders &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Baxter International &nbsp;&nbsp;&nbsp; Takeda Pharmaceutical &nbsp;&nbsp;&nbsp; CSL Limited &nbsp;&nbsp;&nbsp; Octapharma &nbsp;&nbsp;&nbsp; Kedrion Biopharma &nbsp;&nbsp;&nbsp; Bio Products Laboratory &nbsp;&nbsp;&nbsp; LFB group &nbsp;&nbsp;&nbsp; Grifols &nbsp;&nbsp;&nbsp; Lupin Pharmaceuticals

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Primary Immunodeficiency Therapeutic Market Size (2020-2031) &nbsp;2.1.2 Primary Immunodeficiency Therapeutic Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Primary Immunodeficiency Therapeutic by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Primary Immunodeficiency Therapeutic Segment by Type &nbsp;2.2.1 Immunoglobulin Replacement Therapy &nbsp;2.2.2 Stem Cell or Bone Marrow Transplantation &nbsp;2.2.3 Antibiotic Therapy &nbsp;2.2.4 Gene Therapy &nbsp;2.2.5 Others &nbsp;2.3 Primary Immunodeficiency Therapeutic Market Size by Type &nbsp;2.3.1 Primary Immunodeficiency Therapeutic Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Primary Immunodeficiency Therapeutic Market Size Market Share by Type (2020-2025) &nbsp;2.4 Primary Immunodeficiency Therapeutic Segment by Application &nbsp;2.4.1 Antibody Deficiency &nbsp;2.4.2 Cellular Immunodeficiency &nbsp;2.4.3 Innate Immune Disorders &nbsp;2.4.4 Others &nbsp;2.5 Primary Immunodeficiency Therapeutic Market Size by Application &nbsp;2.5.1 Primary Immunodeficiency Therapeutic Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Primary Immunodeficiency Therapeutic Market Size Market Share by Application (2020-2025) 3 Primary Immunodeficiency Therapeutic Market Size by Player &nbsp;3.1 Primary Immunodeficiency Therapeutic Market Size Market Share by Player &nbsp;3.1.1 Global Primary Immunodeficiency Therapeutic Revenue by Player (2020-2025) &nbsp;3.1.2 Global Primary Immunodeficiency Therapeutic Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Primary Immunodeficiency Therapeutic Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Primary Immunodeficiency Therapeutic by Region &nbsp;4.1 Primary Immunodeficiency Therapeutic Market Size by Region (2020-2025) &nbsp;4.2 Global Primary Immunodeficiency Therapeutic Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Primary Immunodeficiency Therapeutic Market Size Growth (2020-2025) &nbsp;4.4 APAC Primary Immunodeficiency Therapeutic Market Size Growth (2020-2025) &nbsp;4.5 Europe Primary Immunodeficiency Therapeutic Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Primary Immunodeficiency Therapeutic Market Size by Country (2020-2025) &nbsp;5.2 Americas Primary Immunodeficiency Therapeutic Market Size by Type (2020-2025) &nbsp;5.3 Americas Primary Immunodeficiency Therapeutic Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Primary Immunodeficiency Therapeutic Market Size by Region (2020-2025) &nbsp;6.2 APAC Primary Immunodeficiency Therapeutic Market Size by Type (2020-2025) &nbsp;6.3 APAC Primary Immunodeficiency Therapeutic Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2020-2025) &nbsp;7.2 Europe Primary Immunodeficiency Therapeutic Market Size by Type (2020-2025) &nbsp;7.3 Europe Primary Immunodeficiency Therapeutic Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Primary Immunodeficiency Therapeutic by Region (2020-2025) &nbsp;8.2 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Primary Immunodeficiency Therapeutic Market Forecast &nbsp;10.1 Global Primary Immunodeficiency Therapeutic Forecast by Region (2026-2031) &nbsp;10.1.1 Global Primary Immunodeficiency Therapeutic Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Primary Immunodeficiency Therapeutic Forecast &nbsp;10.1.3 APAC Primary Immunodeficiency Therapeutic Forecast &nbsp;10.1.4 Europe Primary Immunodeficiency Therapeutic Forecast &nbsp;10.1.5 Middle East & Africa Primary Immunodeficiency Therapeutic Forecast &nbsp;10.2 Americas Primary Immunodeficiency Therapeutic Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.2.2 Canada Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.2.3 Mexico Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.2.4 Brazil Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.3 APAC Primary Immunodeficiency Therapeutic Forecast by Region (2026-2031) &nbsp;10.3.1 China Primary Immunodeficiency Therapeutic Market Forecast &nbsp;10.3.2 Japan Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.3.3 Korea Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.3.4 Southeast Asia Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.3.5 India Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.3.6 Australia Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.4 Europe Primary Immunodeficiency Therapeutic Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.4.2 France Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.4.3 UK Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.4.4 Italy Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.4.5 Russia Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.5 Middle East & Africa Primary Immunodeficiency Therapeutic Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.5.2 South Africa Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.5.3 Israel Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.5.4 Turkey Market Primary Immunodeficiency Therapeutic Forecast &nbsp;10.6 Global Primary Immunodeficiency Therapeutic Forecast by Type (2026-2031) &nbsp;10.7 Global Primary Immunodeficiency Therapeutic Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Primary Immunodeficiency Therapeutic Forecast 11 Key Players Analysis &nbsp;11.1 Baxter International &nbsp;11.1.1 Baxter International Company Information &nbsp;11.1.2 Baxter International Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.1.3 Baxter International Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Baxter International Main Business Overview &nbsp;11.1.5 Baxter International Latest Developments &nbsp;11.2 Takeda Pharmaceutical &nbsp;11.2.1 Takeda Pharmaceutical Company Information &nbsp;11.2.2 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Takeda Pharmaceutical Main Business Overview &nbsp;11.2.5 Takeda Pharmaceutical Latest Developments &nbsp;11.3 CSL Limited &nbsp;11.3.1 CSL Limited Company Information &nbsp;11.3.2 CSL Limited Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.3.3 CSL Limited Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 CSL Limited Main Business Overview &nbsp;11.3.5 CSL Limited Latest Developments &nbsp;11.4 Octapharma &nbsp;11.4.1 Octapharma Company Information &nbsp;11.4.2 Octapharma Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.4.3 Octapharma Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 Octapharma Main Business Overview &nbsp;11.4.5 Octapharma Latest Developments &nbsp;11.5 Kedrion Biopharma &nbsp;11.5.1 Kedrion Biopharma Company Information &nbsp;11.5.2 Kedrion Biopharma Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 Kedrion Biopharma Main Business Overview &nbsp;11.5.5 Kedrion Biopharma Latest Developments &nbsp;11.6 Bio Products Laboratory &nbsp;11.6.1 Bio Products Laboratory Company Information &nbsp;11.6.2 Bio Products Laboratory Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 Bio Products Laboratory Main Business Overview &nbsp;11.6.5 Bio Products Laboratory Latest Developments &nbsp;11.7 LFB group &nbsp;11.7.1 LFB group Company Information &nbsp;11.7.2 LFB group Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.7.3 LFB group Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 LFB group Main Business Overview &nbsp;11.7.5 LFB group Latest Developments &nbsp;11.8 Grifols &nbsp;11.8.1 Grifols Company Information &nbsp;11.8.2 Grifols Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.8.3 Grifols Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Grifols Main Business Overview &nbsp;11.8.5 Grifols Latest Developments &nbsp;11.9 Lupin Pharmaceuticals &nbsp;11.9.1 Lupin Pharmaceuticals Company Information &nbsp;11.9.2 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product Offered &nbsp;11.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Lupin Pharmaceuticals Main Business Overview &nbsp;11.9.5 Lupin Pharmaceuticals Latest Developments 12 Research Findings and Conclusion

Report	Global Primary Immunodeficiency Therapeutic Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI9943

Buyer Information

Order Summary